Down Syndrome Clinical Trials - Study of Alzheimer's Disease in Down Syndrome
Reason given: COVID delayed study timelines. Competing studies began enrolling at our sites.
Key facts
- Where
- Atlanta, Baltimore, Boston, Charlestown, Chicago, Cincinnati, Cleveland, Durham, Fairway, Irvine, La Jolla, Lexington, Park Ridge, and Phoenix, United StatesSee the 14 sites
Where in United States
- Emory UniversityAtlanta, United StatesNo longer taking part
- Kennedy Krieger InstituteBaltimore, United StatesNo longer taking part
- Massachusetts General HospitalBoston, United StatesNo longer taking part
- Massachusetts General HospitalCharlestown, United StatesNo longer taking part
- Rush University Medical CenterChicago, United StatesNo longer taking part
- Cincinnati Children's Hospital Medical CenterCincinnati, United StatesNo longer taking part
- Case Western Reserve UniversityCleveland, United StatesNo longer taking part
- Duke University Medical CenterDurham, United StatesNo longer taking part
- Kansas University Medical CenterFairway, United StatesNo longer taking part
- University California IrvineIrvine, United StatesNo longer taking part
- University of California San DiegoLa Jolla, United StatesNo longer taking part
- University of KentuckyLexington, United StatesNo longer taking part
- Advocate HealthPark Ridge, United StatesNo longer taking part
- Barrow Neurological InstitutePhoenix, United StatesNo longer taking part
Trial details
- Who runs it
- LuMind IDSC Foundation
- Trial code
- NCT04149197
- Record updated
- 27 June 2024
- Original description
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.Read full original descriptionShow less
The Down Syndrome Clinical Trials Network (DS-CTN) Study of Alzheimer's Disease in Down Syndrome
The primary objective is to characterize trajectories of change on the primary outcome measures in this study population through longitudinal collection of measures of cognition, function, behavior, and health status.
Inclusion: Age 25 years or older; Diagnosis of DS, typically supported by karyotype analysis documenting full trisomy for chromosome 21 or complete unbalanced translocation of chromosome 21. Karyotype analysis is not required for study entry; Participants, or Legal Authorized Representative, and their study partner if applicable, in the opinion of the investigator, are able to understand and willing to sign written informed consent; Participants must have a study partner who has frequent interaction with the participant on a regular basis, will agree to participate in annual clinic visits, can provide accurate responses to questions about the participant, and facilitate participation in the study visits, in the opinion of site PI or study coordinator; Participant and study partner must be capable of reliably completing study assessments.